NKGen Releases Additional Phase 1 Data on Alzheimer's Candidate
Monday, 25 March 2024, 22:54
NKGen Announces Promising Data Update on Alzheimer's Candidate
NKGen Biotech has released additional phase 1 data showcasing improvements in cognitive functions and biomarkers in patients who received SNK01, their NK cell therapy.
Key Points:
- Promising Results: The data indicates notable cognitive enhancements and positive changes in biomarkers.
- Significant Progress: The findings suggest a potential breakthrough in Alzheimer's treatment.
Overall, NKGen's research shows promising results in advancing Alzheimer's therapies.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.